Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-0261 in Chronic Spontaneous Urticaria and Healthy Volunteers
NCT07684560Phase 1Not yet recruiting
- Sponsor
- AlphaMol Science
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Alpha-0261 in chronic spontaneous urticaria (CSU) (3 arms), sponsored by AlphaMol Science. Primary endpoint: Frequency of treatment emergent adverse events at 1 week. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Alpha-0261
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07684560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684560.